Related Experiment Video
Updated: Jun 24, 2026
04:22
Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis
Published on: March 3, 2023
Resect first in resectable colorectal liver metastases: recalibrating the default
Rathin Gosavi1,2,3, Mithra Sritharan4, Stephen Bell1
1Department of Colorectal Surgery, Cabrini Health, Melbourne, Victoria, Australia.
Annals of Hepato-Biliary-Pancreatic Surgery
|June 22, 2026
Summary
Perioperative chemotherapy for resectable colorectal liver metastases (CRLM) offers limited survival benefits. Liver-directed therapies and molecular markers may guide selective systemic treatment for better patient outcomes.
Area of Science:
- Hepatobiliary Surgery
- Surgical Oncology
- Gastroenterology
Background:
- Perioperative chemotherapy is standard for resectable colorectal liver metastases (CRLM).
- Evidence for significant survival benefits of perioperative chemotherapy in CRLM remains uncertain.
- Randomized trials have not shown an overall survival (OS) advantage for systemic therapy in resectable CRLM.
